Global Liver Institute
Pediatric & Rare Liver News
GLOBAL LIVER INSTITUTE
Pediatric & Rare Liver Diseases Overview
News
Resources
Membership
Stay up to date with the latest in the Peds & Rare field and subscribe to our monthly newsletters today!
Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News
Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).
Rare Advocacy on Capitol Hill, in the White House, & Beyond! – Pediatric & Rare Liver Diseases News
In February, GLI raised awareness and amplified the patient voice in discussions about transitions in care for rare liver diseases. Here are a few highlights.
It’s Rare Liver Diseases Month! – Pediatric & Rare Liver Diseases News
It’s Rare Liver Diseases Month!
If you haven’t already, join us for the 2024 #RareAware multifaceted campaign, focusing on the theme of “Transitions in Care During.”
For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk
(Washington D.C., February 1, 2023) – Today marks the start of Global Liver Institute’s (GLI) 2024 #RareAware campaign, which calls attention to the more than 100 rare liver diseases throughout February, Rare Liver Diseases Month. Drawing upon insights from patients, caregivers, advocacy groups, clinicians, and other interested parties, the campaign addresses the challenges that transpire when someone with a rare liver disease encounters a transition – whether from pediatric to adult care, from pre- to post-transplant, from inpatient to outpatient care, or another transition.
Building up to Rare Liver Diseases Month
🎉Happy New Year! 🎉 We hope you had time to rest and refresh.
As we step into 2024, we’re excited to continue to bring the latest information and tackle the challenges and opportunities that lie ahead in the pediatric and rare liver diseases field.
Biliary Atresia Patient Registry Launched by BARE Inc!
Chemomab Therapeutics has earned FDA fast track designation for its monoclonal antibody targeting primary sclerosing cholangitis (PSC).